Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clinuvel Pharmaceuticals Ltd (CLVLY)

Clinuvel Pharmaceuticals Ltd (CLVLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVLY with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.0000 +12.13%
on 03/20/24
10.6900 -5.60%
on 04/03/24
+0.0917 (+0.92%)
since 03/15/24
3-Month
8.5400 +18.17%
on 03/12/24
11.1000 -9.08%
on 02/21/24
-0.5983 (-5.60%)
since 01/12/24
52-Week
8.5400 +18.17%
on 03/12/24
13.9200 -27.50%
on 05/02/23
-3.8783 (-27.76%)
since 04/13/23

Most Recent Stories

More News
CLINUVEL progresses vitiligo treatment program

Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide...

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)
Positive final results in stroke

World-first stroke study CUV801 evaluating afamelanotide...

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)
Letter to shareholders from CLINUVEL’s CEO

LONDON, April 29, 2022 (GLOBE NEWSWIRE) --       Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have...

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)
CLINUVEL Expands Pharmaceutical Portfolio

Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders...

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)
CLINUVEL expands DNA Repair Program

SCENESSE ® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V)

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)
CLINUVEL to Trial Innovative Drug in Stroke

MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of afamelanotide,...

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)
First patient dosed in SCENESSE® DNA Repair Program

MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Xeroderma pigmentosum (XP) patient receives SCENESSE ® treatment

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)
CLINUVEL progresses innovative DNA Repair Program

Drug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)
CLINUVEL Opens VALLAURIX R&D Centre In Singapore

Bespoke Research & Development Centre to advance innovative pharmaceutical and OTC products

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)
PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation

Drug to be evaluated in patients with acute and systemic diseases

CUV.AX : 15.150 (-0.33%)
CLVLY : 10.0917 (+3.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 10.5473
2nd Resistance Point 10.3195
1st Resistance Point 10.2056
Last Price 10.0917
1st Support Level 9.8639
2nd Support Level 9.6361
3rd Support Level 9.5222

See More

52-Week High 13.9200
Fibonacci 61.8% 11.8648
Fibonacci 50% 11.2300
Fibonacci 38.2% 10.5952
Last Price 10.0917
52-Week Low 8.5400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar